Empagliflozin Improves Clinical Outcomes and Reduces Mortality in Patients With Diabetes, Cardiovascular Disease, and Chronic Kidney Disease

September 13, 2017. The EMPA-REG OUTCOME trial investigated the impact of empagliflozin, a sodium-glucose cotransporter-2 (SGLT-2) inhibitor, on 7,020 patients with type 2 diabetes (T2D) and cardiovascular (CV) disease. This analysis of a subset of patients with T2D, CV disease, and chronic kidney disease at baseline found that empagliflozin is not only safe, but improves clinical outcomes and reduces mortality when added to standard of care treatment. A total of 2,250 patients with kidney disease, of whom 67% had a T2D diagnosis for at least 10 years at baseline, were randomized to either empagliflozin 10 mg or 25 mg or placebo. Compared with placebo, empagliflozin reduced the risk of CV death, all-cause mortality, hospitalization for heart failure, and all-cause hospitalization by 29%, 24%, 39%, and 19%, respectively. When analyzed by subgroup, or level of kidney function/disease at baseline, the risk-reducing effects of empagliflozin on these outcomes were consistent. This patient subset experienced the same rate of adverse events as the overall trial population. Read the details in the article abstract here